| Literature DB >> 35396589 |
Michele Cassano1, Eugenio De Corso2, Valeria Fiore1, Rossana Giancaspro1, Antonio Moffa1,3, Manuele Casale3, Eleonora Maria Consiglia Trecca1, Dario Antonio Mele2, Pasquale Cassano1, Matteo Gelardi1.
Abstract
Introduction: Nasal endoscopy is likely to be the method of choice to evaluate nasal obstruction and adenoid hypertrophy (AH) in children given its excellent diagnostic accuracy and low risk for the patient. The aim of this study was to update the previous classification of AH to guide physicians in choosing the best therapeutic option. Materials and methods: This is a retrospective observational study including 7621 children (3565 females; mean age 5.92; range: 3-14 years) who were managed for adenoid hypertrophy at our institution between 2003 and 2018. All patients were initially treated with medical therapy and then with surgery if not adequately controlled. We performed a specific analysis based on the presence or absence of comorbidities.Entities:
Keywords: adenoid hypertrophy; classification; nasal endoscopy
Mesh:
Year: 2022 PMID: 35396589 PMCID: PMC9330757 DOI: 10.14639/0392-100X-N1832
Source DB: PubMed Journal: Acta Otorhinolaryngol Ital ISSN: 0392-100X Impact factor: 2.618
Comorbidities according to the 4 different grades of AH.
| Grade | Recurrent nasal secretions | Recurrent tonsilitis | OME | Recurrent AOM | Referred sleep disturbance | Recurrent lower airway diseases | Allergic rhinitis | OSAS |
|---|---|---|---|---|---|---|---|---|
| Grade I (1845 pts – 24.21%) | 72 (3.9%) | 41 (2.2%) | 43 (2.3%) | 21 (1.1%) | 85 (4.6%) | 11 (0.6%) | 30 (1.6%) | 13 (0.7%) |
| Grade II (2829 pts – 37.12%) | 218 (7.7%) | 54 (1.9%) | 75 (2.6%) | 51 (1.8%) | 275 (9.7%) | 20 (0.7%) | 94 (3.3%) | 32 (1.1%) |
| Grade III (1611 pts – 21.14%) | 962 (59.7%) | 89 (5.5%) | 208 (12.9%) | 84 (5.2%) | 983 (61%) | 75 (4.6%) | 207 (12.8%) | 199 (12.3%) |
| Grade IV (1336 pts – 17.53%) | 1336 (100%) | 107 (8%) | 324 (24.2%) | 127 (9.5%) | 1332 (99.7%) | 101 (7.5%) | 340 (25.4%) | 300 (22.4%) |
| Total (7621) | 2588 (33.9%) | 291 (3.8%) | 650 (8.5%) | 283 (3.7%) | 2675 (35.1%) | 207 (2.7%) | 671 (8.8%) | 544 (7.1%) |
OME: otitis media with effusion; AOM: acute otitis media; OSAS: Obstructive Sleep Apnea.
Results of medical therapy in Grade III obstruction.
| Nasal obstruction | Nasal secretions | Lower airway disease | Otitis | Referred sleep disturbance | |
|---|---|---|---|---|---|
| Patients (1611) | 1611 | 962 | 2 | 114 | 982 |
| Unchanged | 654 (40.6%) | 693 (72%) | 2 (100%) | 59 (51.8%) | 599 (61%) |
| Resolved | 161 (10%) | 217 (22,6%) | / | 12 (10.5%) | 101 (10.3%) |
| Improved | 720 (44.7%) | 52 (5,4%) | / | 29 (25.4%) | 174 (17.7%) |
| Worsened | 76 (4.7%) | / | / | 14 (12.7%) | 108 (11%) |
Figure 1.Results of medical therapy on symptoms and comorbidities in Grade III patients.
Figure 2.Flow-chart of diagnostic and therapeutic management of AH.
Results of surgical therapy in Grade III of adenoid hypertrophy (AH).
| Nasal obstruction | Nasal secretions | Lower airway disease | Otitis | Referred sleep disturbance | |
|---|---|---|---|---|---|
| Patients (691) | 691 | 668 | 2 | 73 | 610 |
| Unchanged | / | 2 (0.3%) | / | / | 7 (1.1%) |
| Improved | 178 (25.8%) | 92 (13.8%) | / | 22 (30.6%) | 180 (29.6%) |
| Resolved | 513 (74.2%) | 574 (85.9%) | 2 (100%) | 51 (69.4%) | 423 (69.3%) |
| Worsened | / | / | / | / | / |
Figure 3.Results of surgery on comorbidities.